Docoh
Loading...

55 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
on the date of grant. The fair value of the warrants granted was estimated using the Black-Scholes option pricing model at the date of grant. During
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
on the date of grant. We estimate the fair value of stock option and warrant grants using the Black-Scholes option pricing model, and the assumptions used … of the stock options and warrants granted were estimated using the Black-Scholes option pricing model at the date of grant. The RSUs, stock options
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
using the Black-Scholes option pricing model at the date of grant. During the three months ended March 31, 2021, we also agreed to grant 64,556 RSUs
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s … of grant. The fair value of the warrants granted was estimated using the Black-Scholes option pricing model at the date of grant. We also agreed to grant
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
resulting in peak annual sales of approximately $1.1 billion, irinotecan has a narrow therapeutic window and includes an FDA “Black Box” warning for both … grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
product for gastroparesis is a dopamine D2 Antagonist metoclopramide (Gimoti®), which includes an FDA “Black Box” warning for tardive dyskinesia (TD … cancers resulting in peak annual sales of approximately $1.1 billion, irinotecan has a narrow therapeutic window and includes an FDA “Black Box
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
cancers resulting in peak annual sales of approximately $1.1 billion, irinotecan has a narrow therapeutic window and includes an FDA “Black Box” warning … grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
sales of approximately $1.1 billion, irinotecan has a narrow therapeutic window and includes an FDA “Black Box” warning for both neutropenia and severe … date. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
billion, irinotecan has a narrow therapeutic window and includes an FDA “Black Box” warning for both neutropenia and severe diarrhea … . We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair
10-Q
2020 Q2
PCSA Processa Pharmaceuticals Inc
5 Aug 20
Quarterly report
3:32pm
billion dollars, irinotecan has a narrow therapeutic window and includes an FDA “Black Box” warning for both neutropenia and severe diarrhea. Its … of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
window and includes an FDA “Black Box” warning for both neutropenia and severe diarrhea. Other adverse effects include leucopenia, lymphocytopenia … stock-based compensation charge is recorded in the period of the measurement date. We estimate the fair value of stock option grants using the Black
8-K
EX-99.2
PCSA Processa Pharmaceuticals Inc
1 Jun 20
Entry into a Material Definitive Agreement
7:01am
has a narrow therapeutic window and dose limiting adverse effects, including a FDA “Black Box” warning for both neutropenia and severe diarrhea
10-Q
2020 Q1
PCSA Processa Pharmaceuticals Inc
15 May 20
Quarterly report
1:23pm
of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
in the period of the measurement date. We estimate the fair value of stock option grants using the Black-Scholes option pricing model … and the application of management’s judgment. The Black-Scholes option-pricing model requires the use of subjective assumptions that include the expected stock price
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
share-based compensation charge is recorded in the period of the measurement date. We estimate the fair value of stock option grants using the Black … and involve inherent uncertainties and the application of management’s judgment. The Black-Scholes option-pricing model requires the use of subjective
10-Q
2019 Q3
PCSA Processa Pharmaceuticals Inc
14 Nov 19
Quarterly report
11:45am
the requisite service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes
10-Q
2019 Q2
PCSA Processa Pharmaceuticals Inc
13 Aug 19
Quarterly report
8:00pm
using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best
10-Q
2019 Q1
PCSA Processa Pharmaceuticals Inc
14 May 19
Quarterly report
1:08pm
over the requisite service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based … period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based … service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing